Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2022 / Cilt: 46 - Sayı: 1

A POTENTIAL TARGET FOR DEVOLOPING BROAD SPECTRUM ANTICANCERS: HEXOKINASE-II

GENİŞ SPEKTRUMLU ANTİKANSER BİLEŞİKLER GELİŞTİRMEYE YÖNELİK POTANSİYEL BİR HEDEF: HEKSOKİNAZ-II

Pages
182–192
Publication Date
2022-01-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Using medicinal chemistry approaches new inhibitors can be designed by determining the heterocycles and functional groups providing selectivity against this isozyme.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: As a result of increased need of glucose, reprogramming the metabolic pathways related to respiration is a significant change in cancer cells which differs them from normal cells and this change is known as “Warburg Phenomenon” because firstly reported by Otto Warburg in 1920s.
📊
Key Findings & Data:Increased glycolysis in cancer cells makes glycolysis pathway an important target for cancer tratment.
💡
Conclusion & Impact:Using medicinal chemistry approaches new inhibitors can be designed by determining the heterocycles and functional groups providing selectivity against this isozyme.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glikoliz · heksokinaz · kanser

Abstract

Objective: As a result of increased need of glucose, reprogramming the metabolic pathways related to respiration is a significant change in cancer cells which differs them from normal cells and this change is known as “Warburg Phenomenon” because firstly reported by Otto Warburg in 1920s. Increased glycolysis in cancer cells makes glycolysis pathway an important target for cancer tratment. Hexokinase (HK), first and one of the rate limiting steps of glycolitic pathway, is an important target through this perspective since the prominent phenotype in cancer cells is HK-II, this makes the development of new therapies against this isozyme possible. Using medicinal chemistry approaches new inhibitors can be designed by determining the heterocycles and functional groups providing selectivity against this isozyme.

Özet

Amaç: Kanser hücrelerinin glikoza duydukları ihtiyaç sonucu solunumla ilgili metabolik yolaklarını yeniden düzenlemesi, kanser hücrelerini normal hücrelerden ayıran önemli değişimlerden biridir ve bu değişim ilk olarak 1920’li yıllarda Otto Warburg tarafından rapor edildiği için “Warburg Fenomeni” olarak bilinir. Kanser hücrelerindeki artmış glikoliz, bu yolağı önemli bir kanser hedefi haline getirir. Glikolizin ilk ve hız kısıtlayıcı basamaklarından biri olan Heksokinaz (HK) enzimi bu açıdan önemli bir hedeftir ve kanser hücrelerinde karşımıza çıkan HK-II’nin baskın olduğu fenotip bu izozime yönelik tedavilerin geliştirilmesini mümkün kılar. Medisinal kimya yaklaşımları kullanılarak bu izozime karşı selektivite sağlayan heterosiklik yapılar ve fonksiyonel gruplar belirlenerek yeni inhibitörler dizayn edilebilir.

🔖

Cite This Article

AKDAĞ, M., ÖZÇELİK, A. B. (2022). A POTENTIAL TARGET FOR DEVOLOPING BROAD SPECTRUM ANTICANCERS: HEXOKINASE-II. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 46 - Sayı: 1, 182–192. https://ajindex.com/articles/384419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Pirastehzad, A., Taghizadeh, A., Jamshidi, A.A. (2020). The formation of cancer stem cells in EMT6/Ro tumor: Hybrid modeling within its micro-environment. Informatics in Medicine Unlocked, 18, 100247. [CrossRef] 2. Valkenburg, K.C., de Groot, A.E., Pienta, K.J. (2018). Targeting the tumour stroma to improve cancer therapy. Nature Reviews Clinical Oncology, 15(6), 366-381. [CrossRef] 3. Hemalatha, T., UmaMaheswari, T., Krithiga, G., Sankaranarayanan, P., Puvanakrishnan, R. (2013). Enzymes in clinical medicine: an overview. Indian Journal of Experimental Biology, 51(10), 777-788. 4. Bobrovnikova-Marjon, E., Hurov, J.B. (2014). Targeting metabolic changes in cancer: novel therapeutic approaches. Annual Review of Medicine, 65, 157-170. [CrossRef] 5. Warburg, O., Wind, F., Negelein, E. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519-530. [CrossRef] 6. Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309-314. [CrossRef] 7. Hundshammer, C., Braeuer, M., Müller, C.A., Hansen, A.E., Schillmaier, M., Düwel, S., Feuerecker, B., Glaser, S.J., Haase, A., Weicherd, W., Steiger, K., Cabello, J., Schilling, F., Hövener, J., Kjaer, A., Nekolla, S.G., Schwaiger, M. (2018). Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized 13C-MRSI. Theranostics, 8(17), 4765. [CrossRef] 8. Mathupala, S.P., Ko, Y.A., Pedersen, P.L. (2006). Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 25(34), 4777-4786. [CrossRef] 9. Lehninger, A.L., Nelson, D.L., Cox, M.M. (2005).
  2. Lehninger Principles of Biochemistry, New York: W.H. Freeman. 10. Courtnay, R., Ngo, D.C., Malik, N., Ververis, K., Tortorella, S.M., Karagiannis, T.C. (2015). Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Molecular Biology Reports, 42(4), 841-851. [CrossRef] 11. Kaelin Jr, W.G., Ratcliffe, P.J. (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell, 30(4), 393-402. [CrossRef] 12. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029-1033. [CrossRef] 13. Gill, K.S., Fernandes, P., O'Donovan, T.R., McKenna, S.L., Doddakula, K.K., Power, D.G., Soden, D.M., Forde, P.F. (2016). Glycolysis inhibition as a cancer treatment and its role in an ant